Vera Therapeutics
VERA
22 hedge funds and large institutions have $186M invested in Vera Therapeutics in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
69.21% more ownership
Funds ownership: 0% → 69.21% (+69%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.5M |
| 2 |
A
Abingworth
London,
United Kingdom
|
+$46M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$45.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$27M |
| 5 |
KXA
KPCB XVI Associates
Menlo Park,
California
|
+$20.9M |
Top Sellers
VERA Hedge Fund Activity: Q2 2021 in Review
22 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q2 2021, worth a combined $186M.
Buyers outnumbered sellers: 22 funds opened new VERA positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $48.5M.
- 22 institutional investors held Vera Therapeutics (VERA) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $186M of Vera Therapeutics stock for Q2 2021.
- 22 funds opened new Vera Therapeutics positions in Q2 2021 and 0 closed out, a net change of +22 holders.
- The largest Vera Therapeutics buyer in Q2 2021 was Fidelity Investments, an estimated $48.5M added.
Based on aggregated 13F filings for Q2 2021.